Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial

被引:12
|
作者
Huang, Yu [1 ]
Chen, Jinnan [1 ]
Ding, Zhaohui [1 ]
Chen, Xi [1 ]
Liang, Xiao [1 ]
Zeng, Xin [2 ]
Xu, Fei [2 ]
Han, Yuehua [3 ]
Lu, Hong [1 ]
机构
[1] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Inst Digest Dis, Div Gastroenterol & Hepatol,Sch Med,NHC Key Lab Di, Shanghai, Peoples R China
[2] Tongji Univ, Shanghai East Hosp, Dept Gastroenterol, Sch Med, Shanghai, Peoples R China
[3] Zhejiang Univ, Dept Gastroenterol, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
Helicobacter pylori; Minocycline; Tetracycline; Rescue therapy; ANTIBIOTIC-RESISTANCE; 2ND-LINE REGIMENS; AMOXICILLIN; METRONIDAZOLE; ERADICATION; DOXYCYCLINE; INFECTION; EFFICACY; SAFETY; SUSCEPTIBILITY;
D O I
10.1007/s00535-023-01991-y
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundTo compare the efficacy and tolerability of minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori (H. pylori) rescue treatment.MethodsThis study was a multi-center, randomized-controlled, non-inferiority trial. Refractory H. pylori-infected subjects with multiple treatment-failure were randomly (1:1) allocated to receive 14-day therapy with esomeprazole 20 mg b.i.d, bismuth 220 mg b.i.d, plus metronidazole 400 mg q.i.d and minocycline 100 mg b.i.d (minocycline group) or tetracycline 500 mg q.i.d (tetracycline group). Primary outcome was H. pylori eradication rate evaluated by C-13-urea breath test at least 6 weeks after the end of treatment. Antibiotic resistance was determined using E test method.ResultsThree hundred and sixty-eight subjects were randomized. The eradication rates in minocycline group and tetracycline group were 88.0% (162/184, 95% CI 83.3-92.8%) and 88.6% (163/184, 95% CI 83.9-93.2%) in intention-to-treat analysis, 98.0% (149/152, 95% CI 95.8-100%) and 97.4% (150/154, 95% CI 94.9-99.9%) in per-protocol analysis, 93.1% (162/174, 95% CI 89.3-96.9%) and 93.1% (163/175, 95% CI 89.4-96.9%) in modified intention-to-treat analysis. Minocycline, tetracycline and metronidazole resistance rates were 0.7%, 1.4% and 89.6%, respectively. Non-inferiority of minocycline was confirmed (P < 0.025). Metronidazole resistance did not affect the efficacy of either therapy. The two therapies exhibited comparable frequencies of adverse events (55.4% vs. 53.3%); almost half of them were mild. Dizziness was the most common adverse events in the minocycline group.ConclusionsMinocycline can be an alternative for tetracycline in bismuth-containing quadruple therapy for H. pylori empirical rescue treatment, irrespective of metronidazole resistance. However, relatively high incidence of adverse events in both regimens should be emphasized.
引用
收藏
页码:633 / 641
页数:9
相关论文
共 50 条
  • [1] Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial
    Yu Huang
    Jinnan Chen
    Zhaohui Ding
    Xi Chen
    Xiao Liang
    Xin Zeng
    Fei Xu
    Yuehua Han
    Hong Lu
    Journal of Gastroenterology, 2023, 58 : 633 - 641
  • [2] Reply to: Minocycline versus tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial
    Huang, Yu
    Lu, Hong
    JOURNAL OF GASTROENTEROLOGY, 2024, 59 (04) : 358 - 358
  • [3] Optimization of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Real-World Evidence Study
    Huang, Yu
    Qiu, Shuhan
    Guo, Yixian
    Chen, Jinnan
    Li, Meixuan
    Ding, Zhaohui
    Zhang, Wei
    Liang, Xiao
    Lu, Hong
    HELICOBACTER, 2024, 29 (05)
  • [4] Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection
    Bang, Chang Seok
    Lim, Hyun
    Jeong, Hae Min
    Shin, Woon Geon
    Choi, Jae Ho
    Soh, Jae Seung
    Kang, Ho Suk
    Yang, Young Joo
    Hong, Ji Taek
    Shin, Suk Pyo
    Suk, Ki Tae
    Lee, Jae Jun
    Baik, Gwang Ho
    Kim, Dong Joon
    GUT MICROBES, 2020, 11 (05) : 1314 - 1323
  • [5] Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial
    Chen, Jinnan
    Guo, Yixian
    Huang, Yu
    Ding, Zhaohui
    Wang, Jing
    Liang, Xiao
    Xu, Ping
    Han, Yaohua
    Lu, Hong
    JOURNAL OF INFECTIOUS DISEASES, 2023, 228 (05) : 511 - 518
  • [6] Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China
    Lu, Hong
    Zhang, Wei
    Graham, David Y.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2013, 25 (10) : 1134 - 1140
  • [7] Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial
    Suo, Baojun
    Tian, Xueli
    Zhang, Hua
    Lu, Haoping
    Li, Cailing
    Zhang, Yuxin
    Ren, Xinlu
    Yao, Xingyu
    Zhou, Liya
    Song, Zhiqiang
    CHINESE MEDICAL JOURNAL, 2023, 136 (08) : 933 - 940
  • [8] Comparative study of allicin-containing quadruple therapy vs. bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: a prospective randomized study
    Li, Huan
    Xia, Xiu-Juan
    Zhang, Lin-Fang
    Chi, Jing-Shu
    Liu, Peng
    Wu, Hao
    Xie, Xiao-Ran
    Tian, De-Lin
    Kun, Kai-Xiao
    Gong, Ren-Jie
    Liu, Xiao-Ming
    Xu, Can-Xia
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (02) : 194 - 200
  • [9] Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy
    Chen, Qi
    Zhang, Wei
    Fu, Qingyan
    Liang, Xiao
    Liu, Wenzhong
    Xiao, Shudong
    Lu, Hong
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (12) : 1736 - 1742
  • [10] Modified quadruple therapy or bismuth-containing quadruple therapy in the first-line treatment of Helicobacter pylori in Turkey
    Yozgat, Ahmet
    Kasapoglu, Benan
    Demirci, Selim
    Sokmen, Fevzi Coskun
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2021, 113 (07) : 490 - 493